Journal Highlight : Precision Oncology
The journal welcomes scholarly contributions related to personalized and targeted approaches in cancer diagnosis, treatment, prevention, and management. This section focuses on research that advances individualized cancer care through the integration of molecular profiling, genomic analysis, biomarker discovery, and data-driven therapeutic strategies aimed at improving clinical outcomes and treatment precision.
The journal encourages submissions in areas including Precision Cancer Medicine, Molecular Oncology, Cancer Genomics, Tumor Profiling, Biomarker Discovery and Validation, Targeted Cancer Therapy, Companion Diagnostics, Pharmacogenomics, Immuno-Oncology, and Personalized Therapeutic Strategies. Research related to Next-Generation Sequencing, Liquid Biopsy Technologies, Cancer Proteomics, Epigenetics in Oncology, Molecular Pathology, and AI-Assisted Precision Oncology is also welcomed.
Submissions focusing on Predictive and Prognostic Biomarkers, Cancer Risk Stratification, Treatment Response Monitoring, Clinical Decision Support Systems, Precision Radiation Oncology, Translational Cancer Research, Clinical Trials in Precision Medicine, and Resistance Mechanisms in Cancer Therapy are encouraged. The journal also welcomes studies evaluating the integration of genomics, bioinformatics, computational biology, and digital technologies into precision cancer care and oncology practice.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Clinical Studies, Translational Research Articles, Case Reports, Molecular Diagnostic Studies, Clinical Trial Reports, and Evidence-Based Policy Analyses that contribute to advancements in precision oncology and cancer medicine.
Through this focus area, the journal aims to support research that enhances personalized cancer care, advances molecular understanding of cancer biology, improves diagnostic and therapeutic precision, and contributes to innovative and evidence-based oncology practices worldwide.
